Mar 28, 2022 / 07:30PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks very much. Good afternoon, everybody. It's my pleasure to be hosting Eiry Roberts, Chief Medical Officer at Neurocrine; and Kyle Gano, Chief Business Development Officer. I think we're going to use this as an opportunity to really kind of dive deeper into some of these pipeline assets and preview some of the data that's coming up.
Questions and Answers:
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior AnalystMaybe to kick things off, maybe, Eiry, I think it'd be interesting if you just give a quick sort of high-level overview of the status of each pipeline program. And then Kyle, maybe you could sort of follow with some just sort of thought strategically on Neurocrine and the types of transactions you've been doing, and as the company matures, if maybe the types of transactions you might be willing to do either from a
Trustpilot
